CD209 and non-small cell lung carcinoma: Because A) IL6 has been implicated in NSCLC poor progression basing on clinical reports [28], B) immunostaining derived from LLC tumor tissue showed IL6 accumulated in F4/80+ macrophages areas (Fig. S2B), and C) anti-IL6 antibody impaired the increase of M2 macrophages (CD209+) induced by LLC-CM under hypoxic condition (Fig. S2C), we were thus encouraged to gain specific insight into the phenotype shift of macrophages during hypoxia by applying the IL6.